
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …

Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and putting the patient at the …

People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …
Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships (EHP) Awards recognise outstanding collaborations …

By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, access, and willingness to enrol. …

EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of …

Newel Health, a European healthtech company specialising in digital medical devices, has announced that Amicomed, its digital platform for hypertension …

GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global …

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered …

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …